Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis has demonstrated benefits of an investigational, once-a-day pill called brenso catib as a therapy for the chronic lung condition. It may soon become the first-ever FDA-approved treatment for bronchiectasis.
Quelle: ScienceDaily | Asthma
Titelbild/Grafik: ScienceDaily News
Kommentare und Fragen
Möchten Sie zu diesem Inhalt ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!
Weiteres von ScienceDaily | Asthma
- New drug shows promise for treating bronchiectasis
- Study identifies new method for improving lung growth and function in preterm infants
- School-based asthma therapy improves student health, lowers medical costs
- Better tools when searching for genetic causes of asthma
- Surgery doesn't always help with chronic rhinosinusitis -- a new risk score predicts treatment efficacy
- Adopting zero-emission trucks and buses could save lives, prevent asthma
- Global warming can lead to inflammation in human airways, new research shows
- Routine asthma test more reliable in the morning and has seasonal effects, say doctors
- Stopping asthma in its tracks
- A treatment-resistant, severe type of asthma successfully modeled in mice
